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erated in the presence of iron (4) and this has been used as a
possible explanation for the higher incidence of ischemic heart
disease in young and middle-aged men compared to premeno-
pausal women, as ferritin concentrations are three times higher in
men than in premenopausal women (5). In contrast, more recently
published data, like the studies by Aronow (6), Moore et al. (7),
and Ascherio and colleagues (8), do not support the hypothesis of
a relationship between serum ferritin and atherosclerosis risk.
It is noteworthy that the putative role of iron in the develop-
ment of atherosclerosis is based primarily on clinical and epidemi-
ological studies. However, only few reports investigating correla-
tions between serum concentration of ferritin and anatomic
diagnosis of coronary atherosclerosis assessed by coronary arteriog-
raphy are available in the published data. We (9) could recently
demonstrate that, in patients referred for coronary angiography,
higher ferritin concentrations and transferrin-saturation levels (as
measures of the amount of circulating iron available to tissues) are
not associated with an increased extent of coronary atherosclerosis
(as assessed angiographically). In that study (9), estimates of the
relative risk of coronary heart disease for the quintile with the
highest concentration of serum ferritin as compared with the
lowest quintile were 0.83 (95% confidence interval, 0.63 to 1.24).
Another important point seems to be that all the iron indicators
used to relate iron status to coronary artery disease (CAD) are
affected by inflammation. As a result, an association between CAD
and higher serum ferritin levels could be confounded by inflam-
mation (10). A shortcoming of the study by Gaenzer et el. (1) is
the lack of information on inflammatory markers such as
C-reactive protein.
In summary, early functional and structural vascular abnormal-
ities in patients with hereditary hemochromatosis may predict both
extent of coronary atherosclerosis and the risk of cardiovascular
events in this particular patient group, but in subjects without
hereditary hemochromatosis our results and data from others do
not support the hypothesis that body iron stores, as measured by
serum ferritin and transferrin saturation, are related to the risk of
CAD. In patients with hereditary hemochromatosis, enhancement
of atherogenesis may involve additional mechanisms beyond iron.
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REPLY
We agree with Dr. Auer and colleagues that ferritin levels in our
study (1) may be both a reflection of increased iron stores linked to
primary iron overload and an indication of a chronic inflammation,
as ferritin expression is also regulated by inflammatory cytokines
(2,3).
To rule out the possibility that increased ferritin levels in
hemochromatotic patients are a reflection of an ongoing inflam-
matory response we performed conventional serum tests for
C-reactive protein (CRP), which were all normal in the hemo-
chromatotic subjects included in our study. However, we cannot
rule out that by using a high-sensitive CRP assay we could have
found low-grade inflammation not detected by the conventional
test (4), which would have been of interest because, at least in
diabetics, elevated levels of CRP have been associated with early
structural changes of arteries (5) and because iron is known to
increase formation of hydroxyl radicals during an inflammatory
process (6), which will then exert harmful effects toward the
endothelium.
However, in our study, changes in endothelial-dependent dila-
tion (EDD) very well correlated with transferrin saturation in a
way that higher transferin saturation (TfS) was associated with
increased oxidative stress, increased intima-media thickness, and
decreased EDD. This observation argues against an important role
of inflammation in our setting. This notion is based on the fact
that, during inflammation, drastic changes in iron homeostasis and
distribution occur, which frequently lead to the development of
anemia of chronic disease (7). This condition is characterized by
high ferritin levels and low transferrin saturation, the later just
being the opposite of what is observed in hemochromatotic
patients, even in our study.
Finally, our data demonstrate a close relationship among iron
overload, impaired EDD, and increased intima-media thickness,
which may not be primarily referred to an underlying inflammatory
condition. Nonetheless, determination of high-sensitive CRP will
be attractive to see whether iron overload may induce low-grade
inflammation in hemochromatotic patients.
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Cost-Effectiveness of a Heart Failure
Management Program From the
Societal Perspective?
I read with great interest the study by Capomolla et al. (1), which
was recently published in this Journal. The investigators assessed
the cost-effectiveness of an interdisciplinary heart failure manage-
ment program delivered by day-hospital compared with usual care.
In times of increasing pressures to contain health care resource
consumption, the study by Capomolla and colleagues represents an
important contribution to the literature.
The investigators state that their cost-effectiveness analysis was
conducted from the societal perspective, whereas it actually repre-
sents an analysis from the health care perspective. When defining
the perspective of an economic evaluation, the following key issues
need to be considered in order to be in line with a societal
viewpoint:
The type of costs in economic evaluation. In an analysis from
the societal perspective, all costs are included. In addition to health
care costs, productivity costs should have been assessed (2,3). This
is important if the age of the study population is relatively young.
The average age in the study by Capomolla et al. (1) was 56 years.
The researchers might have therefore missed a significant propor-
tion of the costs from a societal perspective, thereby probably
underestimating the cost-effectiveness of the interdisciplinary heart
failure management program, a program that might help to avert
future production losses in that it enables the sick person to work
again or work until later in his or her life.
Time horizon of the analysis. From an economic perspective,
the appropriate time horizon for a trial would include all of the
time when there is resource use related to heart failure (4). Because
heart failure is a chronic disease, a life-long treatment/
management is necessary. Accordingly, to agree with a societal
perspective, the follow-up period of 12  3 months of the
within-trial evaluation might have been expanded within a mod-
eling framework. In such a simulation study, one would describe
the course of the disease with and without the intervention for a
patient’s lifetime. The simulated societal costs and (untruncated)
life-expectancy resulting from the two strategies would then be
compared in an incremental analysis.
The utility of health states. The utility values were elicited
from patients using the time trade-off technique. In a societal
cost-effectiveness analysis, it is not the patients’ utilities but the
utilities that society attributes to the health states experienced by
the patient that should be included in the study. That is, a random
sample of the general public should have been asked to estimate
utilities from the societal perspective. Alternatively, the EuroQoL
questionnaire (5), a generic measure of quality of life, could have
been administered to the patients in the study. Value sets are
available that can be used to attach societal utility values to the
health states described by the patient in the EuroQoL question-
naire.
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We thank Dr. Sendi for the methodological considerations of our
study.
The type of costs in economic evaluation. In our economic
analysis we considered both direct health costs and indirect costs
(as missing profit). The choice of evaluating the former costs was
a consequence of the management strategy. In the analysis of
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